$22M is nothing if you don't spend it correctly, a lot of biotech start-up I've invest in have done CR for $20M and managed to use it for 3-4 years but mind you they don't have expenditure of $6-8M per quarter which has only happened when AHZ was "trying" to get ADAPT to the market, hopefully with this "transformational" change, management can control their expenditure to $4M.
do not advertise external links.au/...ocel-and-vascucel-for-362-million-904705.html
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-112
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.96 |
Change
-0.040(0.27%) |
Mkt cap ! $310.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.36 | $52.45K | 3.576K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156 | $14.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.96 | 609 | 2 |
View Market Depth
| Last trade - 14.47pm 15/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |